Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Estimation of the warfarin dose with clinical and pharmacogenetic data.

International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA.

N Engl J Med. 2009 Feb 19;360(8):753-64. doi: 10.1056/NEJMoa0809329. Erratum in: N Engl J Med. 2009 Oct 15;361(16):1613. Dosage error in article text.

2.

Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.

Bazan NS, Sabry NA, Rizk A, Mokhtar S, Badary O.

Int J Clin Pharm. 2012 Dec;34(6):837-44. doi: 10.1007/s11096-012-9678-3. Epub 2012 Jul 27.

PMID:
22851439
3.

[Anticoagulation with warfarin].

Schinzel H, Nitschmann S.

Internist (Berl). 2009 Aug;50(8):1026-8. doi: 10.1007/s00108-009-2429-4. German. No abstract available.

PMID:
19499193
4.

Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation.

Xu Q, Xu B, Zhang Y, Yang J, Gao L, Zhang Y, Wang H, Lu C, Zhao Y, Yin T.

Thromb Haemost. 2012 Dec;108(6):1132-40. doi: 10.1160/TH12-05-0362. Epub 2012 Sep 26.

PMID:
23015069
5.

Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.

Ekladious SM, Issac MS, El-Atty Sharaf SA, Abou-Youssef HS.

Mol Diagn Ther. 2013 Dec;17(6):381-90. doi: 10.1007/s40291-013-0046-3.

PMID:
23839801
6.

Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients.

Takeuchi F, Kashida M, Okazaki O, Tanaka Y, Fukuda S, Kashima T, Hosaka S, Hiroe M, Kimura S, Kato N.

Circ J. 2010 May;74(5):977-82. Epub 2010 Mar 26.

7.

Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.

Schwartz JB, Kane L, Moore K, Wu AH.

J Am Med Dir Assoc. 2011 Nov;12(9):633-8. doi: 10.1016/j.jamda.2010.12.006. Epub 2011 Jan 26.

PMID:
21450231
8.

Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.

Cho HJ, On YK, Bang OY, Kim JW, Huh W, Ko JW, Kim JS, Lee SY.

Clin Ther. 2011 Oct;33(10):1371-80. doi: 10.1016/j.clinthera.2011.09.004. Epub 2011 Oct 6.

PMID:
21981797
9.

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL.

J Thromb Thrombolysis. 2006 Dec;22(3):191-7.

PMID:
17111199
10.

A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms.

Cini M, Legnani C, Cosmi B, Guazzaloca G, Valdrè L, Frascaro M, Palareti G.

Eur J Clin Pharmacol. 2012 Aug;68(8):1167-74. doi: 10.1007/s00228-012-1226-5. Epub 2012 Feb 19.

PMID:
22349464
11.

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.

Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL.

Clin Pharmacol Ther. 2008 Sep;84(3):326-31. doi: 10.1038/clpt.2008.10. Epub 2008 Feb 27. Erratum in: Clin Pharmacol Ther. 2008 Sep;84(3):430.

12.

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.

Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ.

Pharmacogenomics. 2009 Aug;10(8):1243-55. doi: 10.2217/pgs.09.71.

13.

Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic.

Shaw PB, Donovan JL, Tran MT, Lemon SC, Burgwinkle P, Gore J.

J Thromb Thrombolysis. 2010 Aug;30(2):220-5. doi: 10.1007/s11239-010-0459-3.

PMID:
20204461
14.

Validation of warfarin pharmacogenetic algorithms in clinical practice.

Marin-Leblanc M, Perreault S, Bahroun I, Lapointe M, Mongrain I, Provost S, Turgeon J, Talajic M, Brugada R, Phillips M, Tardif JC, Dubé MP.

Pharmacogenomics. 2012 Jan;13(1):21-9. doi: 10.2217/pgs.11.120.

PMID:
22176621
15.

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.

Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, Pendleton RC, McMillin GA, Burmester JK, Kurnik D, Stein CM, Caldwell MD, Eby CS, Rane A, Lindh JD, Shin JG, Kim HS, Angchaisuksiri P, Glynn RJ, Kronquist KE, Carlquist JF, Grice GR, Barrack RL, Li J, Gage BF.

Thromb Haemost. 2012 Feb;107(2):232-40. doi: 10.1160/TH11-06-0388. Epub 2011 Dec 21.

16.

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F.

Blood. 2005 Oct 1;106(7):2329-33. Epub 2005 Jun 9.

17.

Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.

Shalia KK, Doshi SM, Parikh S, Pawar PP, Divekar SS, Varma SP, Mehta R, Doctor T, Shah VK, Saranath D.

J Assoc Physicians India. 2012 Dec;60:34-8.

PMID:
23781667
18.

VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.

Biss TT, Avery PJ, Brandão LR, Chalmers EA, Williams MD, Grainger JD, Leathart JB, Hanley JP, Daly AK, Kamali F.

Blood. 2012 Jan 19;119(3):868-73. doi: 10.1182/blood-2011-08-372722. Epub 2011 Oct 18.

19.

Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.

Teh LK, Langmia IM, Fazleen Haslinda MH, Ngow HA, Roziah MJ, Harun R, Zakaria ZA, Salleh MZ.

J Clin Pharm Ther. 2012 Apr;37(2):232-6. doi: 10.1111/j.1365-2710.2011.01262.x. Epub 2011 Apr 20.

PMID:
21507031
20.

Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.

Linder MW, Bon Homme M, Reynolds KK, Gage BF, Eby C, Silvestrov N, Valdes R Jr.

Clin Chem. 2009 Oct;55(10):1861-8. doi: 10.1373/clinchem.2009.125898. Epub 2009 Aug 13.

Supplemental Content

Support Center